The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells
Open accessAbstract
The optimization of a purely negative depletion, enrichment process for circulating tumor cells (CTCs) in the peripheral blood of head and neck cancer patients is presented. The enrichment process uses a red cell lysis step followed by immunomagnetic labeling, and subsequent depletion, of CD45 positive cells. A number of relevant variables are quantified, or attempted to be quantified, which control the performance of the enrichment process. Six different immunomagnetic labeling combinations were evaluated as well as the significant difference in performance with respect to the blood source: buffy coats purchased from the Red Cross, fresh, peripheral blood from normal donors, and fresh peripheral blood from human cancer patients. After optimization, the process is able to reduce the number of normal blood cells in a cancer patient's blood from 4.05 × 10 9 to 8.04 × 10 3 cells/mL and still recover, on average, 2.32 CTC per mL of blood. For all of the cancer patient blood samples tested in which CTC were detected (20 out of 26 patients) the average recovery of CTCs was 21.7 per mL of blood, with a range of 282 to 0.53 CTC. Since the initial number of CTC in a patient's blood is unknown, and most probably varies from patient to patient, the recovery of the CTC is unknown. However, spiking studies of a cancer cell line into normal blood, and subsequent enrichment using the optimized protocol indicated an average recovery of approximately 83%. Unlike a majority of other published studies, this study focused on quantifying as many factors as possible to facilitate both the optimization of the process as well as provide information for current and future performance comparisons. The authors are not aware any other reported study which has achieved the performance reported here (a 5.66 log 10) in a purely negative enrichment mode of operation. Such a mode of operation of an enrichment process provides significant flexibility in that it has no bias with respect to what attributes define a CTC; thereby allowing the researcher or clinician to use any maker they choose to define whether the final, enrich product contains CTCs or other cell type relevant to the specific question (i.e., does the CTC have predominately epithelial or mesenchymal characteristics?). Biotechnol. Bioeng. 2009;102: 521–534. © 2008 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kokkinos, M. I., Wafai, R., Wong, M. K., Newgreen, D. F., Thompson, E. W., & Waltham, M. (2007) · Cells Tissues Organs · doi:10.1159/000101320 · Cited by 394
Red blood cell magnetophoresis
Zborowski, M., Ostera, G. R., Moore, L. R., Milliron, S., Chalmers, J. J., & Schechter, A. N. (2003) · Biophysical Journal · doi:10.1016/s0006-3495(03)75069-3 · Cited by 260
Self-citation
Cited by
Challenges in circulating tumour cell research
Alix-Panabières, C., & Pantel, K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3820 · Cited by 1,300
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
Haber, D. A., & Velculescu, V. E. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1014 · Cited by 694
Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics
Warkiani, M. E., Khoo, B. L., Wu, L., Tay, A. K. P., Bhagat, A. A. S., Han, J., & Lim, C. T. (2016) · Nature Protocols · doi:10.1038/nprot.2016.003 · Cited by 548
Circulating tumor cell technologies
Ferreira, M. M., Ramani, V. C., & Jeffrey, S. S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.007 · Cited by 511
Metadata
- Authors
- Yang, L., Lang, J. C., Balasubramanian, P., Jatana, K. R., Schuller, D., Agrawal, A., Zborowski, M., & Chalmers, J. J.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2008-08-22
- Volume
- 102
- Issue
- 2
- Pages
- 521-534
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2073017550
- Cited by
- 200
- References
- 2
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.